Systemic lupus erythematosus (SLE) features a decreased pool of CD4
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease (AID) characterized by the destruction of immune regulation 1 , in which defects in Treg cell numbers and/or function have been observed both in patients and in a lupus-prone mouse model [2] [3] [4] [5] [6] . The mechanisms underlying the defects or deficiency of T regulatory (Treg) cells are variable, and include reduced capacity of suppression function, increased Treg cell apoptosis and the inhibition of Treg cell differentiation in the presence of high serum levels of proinflammatory cytokines such as interferon (IFN)-α, IFN-γ, interleukin (IL)-6, IL-1β and IL-17 [7] [8] [9] . Most previous studies have focused on how Treg cells regulate effector T cells, B cells, natural killer (NK) cells or antigen-presenting cells (APCs) [10] [11] [12] . However, whether and how T cells regulate Treg cells in SLE is unclear. NKG2D + CD4 + T cells are a novel subset of T lymphocytes reported in many AIDs, such as rheumatoid arthritis, Crohn's disease and granulomatosis with polyangiitis (GPA) (Wegener's); these cells interact with NKG2D ligand (NKG2DL)-positive cells, such as synoviocytes, endothelial and epithelial cells. thereby causing autoreactive T cell stimulation and AID [13] [14] [15] . TNF-α and IL-15, which are abundant in inflamed local tissue or peripheral blood, can induce NKG2D expression on CD4 + T cells in RA, GPA and SLE 13, 14, 16, 17 . Recently, NKG2D + CD4 + T cells have been reported to produce IL-17 in type 2 diabetes (T2D) and to exert cytotoxic effects in Crohn's disease and GPA 14, 17, 18 . The NKG2DLs are stress-induced proteins, including the major histocompatibility complex (MHC) class I-chain-related (MIC)A, MICB and UL16-binding protein (ULBP) in humans, as well as the UL16-binding protein-like transcript 1 (Mult-1), histocompatibility 60 (H60) and retinoic acid early inducible-1 (Rae-1) in mice 19 . Normally, these ligands have a restricted tissue distribution in intestinal epithelium and can be induced by stresses such as viral and bacterial infections, malignant transformation and proliferation, thereafter acting as danger signals to alert NK cells and CD8 + T lymphocytes by engaging the NKG2D activating receptor [20] [21] [22] . Therefore, APCs, endothelial and epithelial cells express high levels of NKG2DLs, such as MICA/B as in AID, and interact with NKG2D + cells to aggravate inflammation 21 . Indeed, increased serum level of soluble (s)MICA and extensive expression of MICA in kidneys of patients with lupus nephritis have been implicated in lupus pathogenesis 23, 24 , and expression of the other NKG2DL, ULBP, has been detected in hair follicle dermal sheath in alopecia areata 25, 26 ; however, whether NKG2DLs are expressed on T cells in SLE is not known. Given the aforementioned reduction in Treg cell numbers and abnormal expansion of NKG2D +
CD4
+ T cells, we hypothesized that these two cell subsets may be correlated. Furthermore, because we previously observed aberrant NKG2D expression on CD4 + T cells in SLE 16 , we hypothesized that the NKG2D-NKG2DL interaction links NKG2D + CD4 + T cells and Treg cells in this disease. Here, we provide evidence of significant upregulation of ULBP (Mult-1 in mice) on Treg cells upon lupus serum stimulation. Antibody (Ab) neutralization and direct cytokine stimulation experiments further verified that IFN-α is the main factor in SLE serum that induces ULBP and Mult-1 expression on the Treg cells. NKG2DL
+ Treg cells were killed by NKG2D + CD4 + T cells, the latter of which secreted granzyme and perforin to induce apoptosis of the target cells. However, blocking NKG2D-NKG2DL binding markedly inhibited this cytotoxicity in vitro. Moreover, adoptive transfer experiments suggested that NKG2DL + Treg cells could be killed in a lupus-prone mouse model (MRL/lpr mice), which could be protected by NKG2D blocking. Therefore, our results indicate that NKG2D + CD4 + T cells can kill Treg cells induced to express NKG2DL by IFN-α in a NKG2D-NKG2DL-dependent manner, thereby leading to the dramatic reduction in Treg numbers in SLE and highlighting the NKG2D-NKG2DL interaction as a novel therapeutic target for SLE treatment.
Materials and Methods
Mice. Female C57BL/6 mice (referred to here as B6 mice), B6.MRL-Fas lpr /J mice (referred to here as B6.MRL/ lpr mice) and NZBW/F1 mice (The Jackson Laboratory, Bar Harbor, ME, USA) were maintained in the Animal Facility under pathogen-free conditions according to the guidelines for experimental animals at the Third Military Medical University, Chongqing, China. All animal studies were approved by the Ethics Committee for Animal Experimentation of the Third Military Medical University.
Subjects and blood samples. Peripheral blood samples were obtained from 66 untreated patients with SLE from the Southwest Hospital (Chongqing, China). They all met the American College of Rheumatology (ACR) criteria for SLE 27 . Disease activity was scored according to the SLE Disease Activity Index (SLEDAI) scoring system, with mild/moderate having score 5 < SLEDAI < 14 and severe having score >14. The detailed clinical information of subjects is listed in Supplementary Table 1 . Patients with Sjogren syndrome (n = 5), systemic scleroderma (n = 8) and rheumatoid arthritis (n = 8), were used as disease controls. Healthy volunteer controls (HC; n = 46) with no family history of AID were recruited from Center of Health Examination of the Southwest Hospital. All subjects enrolled in the study provided written informed consent, and all activities were approved by the Ethics Committee of the Third Military Medical University, Chongqing, China. The methods in this study were carried out in accordance with the approved guidelines.
Antibodies and flow cytometry (FCM).
The following anti-human and mouse monoclonal antibodies (eBioscience, San Diego, CA, USA) were used for multiparameter FCM, respectively, anti-CD3-FITC (OKT3 and 17A2), anti-CD8-PerCPCy5.5 (SK1 and 53-6.7), anti-CD14-FITC (61D3 and Sa2-8), anti-CD19-PECy7 (HIB19 and Sa2-8), anti-CD4-PerCPCy5.5 (OKT-4 and GK1.5), anti-APC-CD25 (BC96 and PC61.5) and anti-PE-NKG2D (1D11 and CX5). The anti-human antibodies of anti-CD56-PE (CMSSB), anti-TIM3-APC (F38-2E2), anti-CTLA-4-FITC(14D3), anti-PD1-APC (eBioJ105 (J105)), anti-CD45RA-PerCPCy5. 
CD4
+ T cells from SLE patients at different effector:target ratios, and subjected to standard 51 Cr-release assays 28 . In Abs blocking experiments, neutralizing anti-NKG2D mAb (5 μg/ mL; eBioscience), anti-ULBP1-3 mAb (5 μg/mL; R&D Systems), and anti-FasL mAb (5 μg/mL; eBioscience) were added to the co-culture system. Kidney histology and immunofluorescence staining. OCT-embedded kidney tissue sections from MRL/lpr mice were stained with hematoxylin and eosin (H&E) or antibodies against mouse C3, IgG and IgM followed by the fluorescence-labeled secondary antibodies, all of which were from Abcam (Cambridge, MA, USA). Glomerular, tubulointerstitial and vascular damage were evaluated on H&E-stained slides using a semiquantitative scoring system (0, 1, 2 and 3) 29 .
Fluorescence staining of slides were scored (0-3) in a masked fashion by an experienced renal pathologist for the intensity and coverage of immunofluorescence in the glomerulus (0, no staining; 1+, mild staining; 2+, moderate staining; 3+, strong staining).
Treatment with anti-IFNAR Ab and anti-NKG2D Ab. Female B6.MRL/lpr mice were treated with anti-IFNAR1 mAb (MAR1-5A3; eBioscience) or anti-NKG2D mAb (CX5; eBioscience) as previously described 30, 31 . Anti-IFNAR1 mAb or cIg injections were started at 15 wk of age, when the appearance of disease manifests, as suggested by detectable autoantibody titers and proteinuria (i.p., 500 μg for three consecutive days, followed by 250 μg three times per week until experiment termination). Similarly, injections of anti-NKG2D mAb or cIg were started at the same age (i.p. on days 1 and 5 with 8 μg/g of anti-NKG2D mAb (CX5) twice weekly).
Measurement of cytokine level. Supernatants from serum of SLE patients and MRL/lpr mice were stored at −80 °C until use. The levels of serum and supernatant IFN-α, TNF-α, IL-1β, IL-6, TGF-β and IFN-γ were then measured using an ELISA kit (R&D Systems). Supernatants of the co-cultures comprised of NKG2D + CD4 + T cells and serum-induced Treg cells were collected for measurement of perforin and granzyme B by ELISA kits (LifeSpan BioSciences, Seattle, WA, USA and Genway Biotech, San Diego, CA, USA, respectively).
Statistical analysis.
Statistical analysis was performed using GraphPad Prism 5 software. The Mann-Whitney test was used for comparisons between patients and controls. Comparisons between different groups were performed with Student's t-tests or one-way ANOVA with the Tukey's multiple comparison test, and Spearman's test was used for correlation studies. P < 0.05 was considered significant.
Results

Aberrant expansion of cytotoxic NKG2D
+ CD4 + T cells in the peripheral blood in patients with SLE. NKG2D, the activating NK receptor, is mainly expressed on cytotoxic cells such as NK, NKT and CD8 + T cells, to maintain normal homeostasis, and CD4 + T cells express very low levels of this receptor in healthy individuals [32] [33] [34] . Recent studies have shown an increased percentage of NKG2D + CD4 + T cells in some AIDs, such as rheumatoid arthritis, Crohn's disease and GPA [13] [14] [15] , indicating a possible involvement in AID pathogenesis; however, the underlying mechanism remains largely unclear. In this study, SLE patients showed significantly decreased expression of NKG2D on NK (62.58% ± 1.17 vs HC: 92.91% ± 0.50), NKT (56.88% ± 1.08 vs HC: 90.59% ± 0.60) and CD8 + T (59.39% ± 1.13 vs HC: 90.02% ± 0.62) cell subsets, and remarkably increased expression on CD4 + T cell subsets (19.79% ± 1.01 vs 1.70% ± 0.09) ( Fig. 1A and B) , suggesting the involvement of NKG2D + CD4 + T cells in SLE disease progression. To further define the characteristics of NKG2D + CD4 + T cells in patients with SLE, we detected the activated surface markers and intracellular cytokine profiles of NKG2D + CD4 + T cells from SLE patients. These cells did not express CD25, CTLA-4, TIM-3, PD-1, CD45RO, CCR7 or CD27, but they did express CD45RA, HLA-DR and CD38 (Fig. 1C) . Of note, these cells showed distinct cytotoxicity and pro-apoptotic features, as approximately 40-50% of these cells expressed perforin, granzyme B and FasL (Fig. 1D ), indicating that these cells represent an activated form rather than the naïve state. In addition, these cells did not express the transcription factor Foxp3 or Th2 nor any of the Th17 cell-related cytokines; instead, approximately 30% of the cells secreted IFN-γ, suggesting Th1-like characteristics (Fig. 1D ).
Cytotoxic NKG2D
+ CD4 + T cells correlated with decreased frequency of Treg cells in both SLE patients and B6.MRL/lpr mice. A hallmark of human SLE is lymphocytopenia 35 . In line with this observation, we found that the proportions of total T cells (CD3 Figure 1B and C) . We then analyzed the correlation of the increased NKG2D + CD4 + T cells subsets with these abnormal proportions of lymphocyte subsets in SLE patients. A strong negative correlation was found between Scientific RepoRts | 7: 1288 | DOI:10.1038/s41598-017-01379-y Scientific RepoRts | 7: 1288 | DOI:10.1038/s41598-017-01379-y the frequencies of NKG2D + CD4 + T cells and CD4 + T cells (R 2 = 0.2832, P < 0.0001) in the PBMCs of SLE patients, but no correlation was found for the frequency of CD8 + T cells or CD19 + B cells ( Fig. 2A) . Among the CD4 + T subsets, the frequency of NKG2D + CD4 + T cells was found to be negatively correlated with the frequency of Treg cells (R 2 = 0.4975, P < 0.0001), but not with the frequency of Th1, Th2 or Th17 cells ( Fig. 2A) Figure 2) .
B6.MRL/lpr and NZBW/F1 mice are universal lupus animal models 5, 6 and both showed decreased frequency of Treg cells or of absolute cell numbers in spleen; however, we found that the B6.MRL/lpr mice but not the NZBW/F1 mice showed an increased frequency of NKG2D + CD4 + T cells in our experimental period (Fig. 2B) . Therefore, we adopted the B6.MRL/lpr lupus mouse model for this study, since they could mimic the clinical features of SLE patients with respect to NKG2D + CD4 + T cells. We then analyzed the correlation of the NKG2D + CD4 + T cells with the various types of lymphocytes in the B6.MRL/lpr mice. Similar results were obtained as in SLE patients, which showed NKG2D + CD4 + T cells frequency is inversely correlated to the frequency of CD4 + T cells (R 2 = 0.3830, P = 0.0139) and Treg cells (R 2 = 0.6089, P = 0.0006), respectively (Fig. 2C) (Fig. 3A) . The NKG2D + CD4 + T cells from the SLE patients efficiently killed the NKG2DL + Treg cells (Fig. 3B) , accounting for the negative expression of NKG2DLs on CD3 + CD4 + T cells from SLE patients (Supplementary Figure 3) . Furthermore, this cytotoxicity was NKG2D/NKG2DL-dependent since the addition of blocking antibodies against NKG2D or the NKG2DLs, ULPB1-3, significantly downregulated the cytotoxicity (Fig. 3B) . The underlying effector mechanism, at least partially, involved the Fas/FasL apoptosis pathway, since addition of neutralizing antibodies against FasL markedly reduced this effect (Fig. 3B ). In addition, monocytes that express NKG2DLs were isolated from SLE patients for use as the positive control of target cells. Results showed that these monocytes could be killed by NKG2D + CD4 + T cells (Supplementary Figure 4) , suggesting that the cytotoxicity of NKG2D + CD4 + T cells involved various targets in SLE. Notably, we found that the induction of the NKG2DLs ULBP1-3 expression was specific for SLE serum, since serum from patients with Sjogren syndrome, systemic scleroderma or rheumatoid arthritis did not induce the expression of NKG2DLs on Treg cells (Fig. 3A) . Moreover, when we categorized the SLE serum according to mild/moderate or severe disease status (according to the SLEDAI index), we found higher expression of ULBPs on Tregs induced by SLE serum from severe patients, as compared to that from mild/moderate patients (Fig. 3A) . However, SLE serum did not induce the expression of any NKG2DLs on CD4 + CD25 -T responder (Tres) cells (Fig. 3A) .
Adoptive transferred NKG2DL
+ Treg cells were killed by NKG2D + CD4 + T cells in B6.MRL/lpr mice. Similar to the findings of SLE patients (Supplementary Figure 3) , both B6.MRL/lpr and B6 control mice showed undetectable expression of NKG2DLs (Mult-1, the counterpart of human ULBPs; H60; Rae-1) on the CD3 + CD4 + T cells (Supplementary Figure 5) . To further investigate whether the NKG2D + CD4 + T cells exert similar cytotoxic effects on NKG2DL + Treg cells in vitro and in vivo, we stimulated Treg cells isolated from B6 control mice with B6.MRL/lpr mice serum and found that the NKG2DL Mult-1, but not H60 or Rae-1, was significantly upregulated (Fig. 4A) . ELISA assay showed marked increase of perforin and granzyme B derived from the NKG2D + CD4 + T cells co-cultured with lupus serum that stimulated Treg cells, indicating that NKG2D + CD4 + T cells could kill target cells by secreting cytotoxic mediators in vitro (Fig. 4B) . Moreover, after adoptive transfer tothe B6.MRL/lpr mice, the NKG2DL + Treg cells were efficiently killed by NKG2D + CD4 + T cells in vivo (Fig. 4C) , and pre-treatment with anti-NKG2D mAb in MRL/lpr mice showed an obvious restoration of the exogenous Treg cells frequency (Fig. 4C ). All these results indicated that the cytotoxicity of NKG2D on Treg cells. To further investigate the cytokine types that may be involved in the NKG2DLs induction, we firstly measured the levels of IFN-α, IFN-γ, IL-6, IL-1β and TNF-α in B6.MRL/lpr mice serum by ELISA. It was found that, although all these cytokines showed elevated levels in lupus serum (Supplementary Figure 6A) , only anti-IFNAR Abs were able to obviously downregulate the induction of NKG2DL Mult-1 expression (Fig. 5A) , which was consistent with the finding of high IFNAR expression on Treg cells in MRL/lpr mice (Supplementary Figure 6B) . Accordingly, recombinant murine IFN-α remarkably induced Mult-1 expression on Treg cells isolated from B6.MRL/lpr mice, which was comparable with the induction effects by B6.MRL/lpr serum (Fig. 5B ). All these data suggested that, IFN-α was the major cytokine responsible for the induction of expression of NKG2DLs on the Treg cells in B6.MRL/lpr mice. To further investigate whether the IFN-α/IFNAR pathway also plays a critical role in the induction of NKG2DLs ULBPs on human Treg cells, we measured IFN-α in SLE patients' serum and IFNAR expression on Treg cells, it was found that IFN-α levels ( Fig. 5C ; P < 0.0001) and IFNAR1/R2 expression in SLE patients were remarkably increased compared with HCs ( Fig. 5D ; IFNAR1: P = 0.0090 and IFNAR2: P < 0.0001). Moreover, severe SLE patients showed higher serum levels of IFN-α (Fig. 5C , P < 0.0001) and IFNAR1/R2 expression than 
CD4
+ T cells and T cell subsets and B cells in B6.MRL/lpr mice. The correlation coefficient and P value are indicated. the mild/moderate SLE patients ( Fig. 5D ; IFNAR1: P < 0.0001 and IFNAR2: P < 0.0001). Blocking IFN-α/IFNAR signaling by anti-IFNAR mAb remarkably downregulated the ULBPs induction on Treg cells (Fig. 5E ). All these data indicated that IFN-α/IFNAR signaling is responsible, at least partially, for the induction of NKG2DLs on Treg cells in patients with SLE.
Furthermore, we performed co-culture assay to demonstrate that IFN-α is directly involved in the mechanism underlying the increased ULBPs expression on Treg cells, and thus leading to the reduction of Treg cells in SLE. Treg cells from healthy controls were stimulated with IFN-α and the viable Treg cells were sorted and co-cultured with NKG2D +
+ T cells, with or without anti-ULBPs mAbs. Results showed that NKG2D + CD4 + T cells could efficiently kill these Treg cells and that blocking the NKG2D-ULBPs interaction by anti-ULBPs mAbs significantly inhibited the cytolysis effect on Treg cells (Fig. 5F) , which was further supported by the absolute counts of viable Treg cells in the co-culture system (Fig. 5G) . It should be noted that we also found that IFN-α could induce apoptosis of Treg cells, that the frequency of apoptotic Treg cells was markedly increased, as compared to that of the PBS control (Supplementary Figure 7A) , and that the viable Treg cell frequency was significantly decreased by SLE serum, as compared to HC serum (Supplementary Figure 7B) . Collectively, these data indicated that the IFN-α/IFNAR pathway is a primary mediator of the induction of NKG2DLs on Treg cells and, thereby, the reduction of Treg cells in patients with SLE. In contrast to these findings with Tregs, CD45RO + CD4 + memory T cells could only slightly induce the ULBPs expression by IFN-α (Supplementary Figure 8) . Cr and irradiated (25 Gy), co-cultured for 6-8 h with NKG2D + CD4 + T cells from SLE patients, and subjected to cytotoxicity assay, and assessed for the 51 Cr-release at the indicated effector:target ratios; the experiment was performed with or without pre-incubation with the indicated neutralizing antibodies. Data represent three independent experiments with Treg cells from HC.
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Blockade of IFN-α/IFNAR or NKG2D restored Treg cells frequency and alleviated lupus disease in B6.MRL/lpr mice. The above results indicated that the reduction of Treg cells in SLE was involved
with the increased NKG2DLs expression induced by IFN-α, so we treated B6.MRL/lpr mice with neutralizing anti-IFNAR mAb or anti-NKG2D mAb. The results showed that the frequency of the Treg cells was restored to a level comparable to that in C57BL/6 control mice after 5 successive weeks of anti-IFNAR mAb treatment (7.62% vs 8.14%, P = 0.32) or anti-NKG2D mAb (7.14% vs 8.14%, P = 0.1) (Fig. 6A) . Furthermore, most disease parameters showed significant reduction. Compared to isotype IgG treatment, anti-IFNAR mAb or anti-NKG2D mAb treatment of B6.MRL/lpr mice led to a significant reduction in serum levels of the antinuclear antibodies (ANA) autoantibodies (anti-IFNAR mAb: P < 0.0001 and anti-NKG2D mAb: P = 0.0083; Fig. 6B ) and ds-DNA (anti-IFNAR mAb: P < 0.0001 and anti-NKG2D mAb: P = 0.0006; Fig. 6B ), an obvious improvement in glomerulonephritis (GN) with decreased glomerular hypercellularity and mesangial cell proliferation, a remarkable down-regulation in the kidney deposits (IgG, IgM and C3) (Fig. 6C) , a marked reduction in splenomegaly and lymphadenophthy (Fig. 6D) , and a significant increase in the survival rate (Fig. 6E) .
Discussion
SLE patients show a significantly decreased Treg cell frequency, which might be responsible for the severe immune homeostasis disorder that defines this AID [2] [3] [4] [5] [6] . Nevertheless, the mechanism underlying the decrease in Treg cells number remains unclear. In this study, SLE patient samples and the B6.MRL/lpr lupus mouse model were both found to have an association between the significantly decreased Treg cell frequency and marked expansion in the NKG2D
+ CD4 + T cell population. Moreover, the NKG2D + CD4 + T cells were found to express cytotoxic and proapoptotic factors such as perforin, granzyme B and FasL, which efficiently killed Treg cells that were induced by IFN-α to express NKG2DLs in vitro. Furthermore, adoptively transferred NKG2DL + Treg cells were also found to be killed in the B6.MRL/lpr lupus mice in a NKG2D-NKG2DL dependent manner. Anti-IFNAR or anti-NKG2D treatment of B6.MRL/lpr mice remarkably restored Treg cell numbers and ameliorated the lupus disease, confirming the substantial contribution of NKG2D + CD4 + T cells to the decrease in Treg cells observed in SLE patients.
In contrast to the significantly decreased NKG2D expression on CD8 + T, NK and NKT cells, we observed a marked increase in NKG2D
+ CD4 + T cells in SLE patients, in both the present study and in our previous work 16 . It has been demonstrated in several other studies that sTNF-α and sIL-15, which are abundant in inflamed tissue or peripheral blood, can induce NKG2D expression on CD4 + T cells 13, 16, 17 . Moreover, NKG2D + CD4
+ T cells have been demonstrated to exhibit cytotoxic features in Crohn's disease, being capable of killing target C1R cells (a human B-cell lymphoblastoid line that lacks surface HLA A and B antigens) that had been transfected with MICA in vitro 14 . NKG2D + CD4 + T cells are also able to kill vascular endothelial cells in GPA disease 17 . In the present study, we demonstrated that NKG2D +
CD4
+ T cells from SLE patients secreted perforin and granzyme B, as well as the Th1-cytokine IFN-γ, mirroring the features of the NKG2D + CD4 + T cells in Crohn's disease and GPA 14, 17 . Furthermore, the NKG2D + CD4 + T cells were able kill SLE serum-induced NKG2DL + Treg cells in a NKG2D-dependent manner. This is the first study to demonstrate that the abnormally increased NKG2D + CD4 + T cells of SLE can kill NKG2DL + Tregs, and the findings contrast the previous report of chimeric NKG2D-transduced CD8 + T cells killing NKG2DL + Treg cells in a murine model of ovarian cancer 36 . Although it has been demonstrated that NK cells could lyse expanded Treg cells stimulated by tuberculosis bacteria (T.B.) in an NKG2D-dependent manner 28 , those findings were obtained from experiments using the in vitro T.B. stimulation assay. As such, that study was able to confirm that cytokine-activated NK cells could Cr-release assay and apoptosis assay, respectively. All values represent the mean ± SD of three independent experiments. ** P < 0.01, *** P < 0.001.
kill stimulated Tregs, but it did not reflect the in vivo state of NK cells in SLE patients. Actually, in SLE patients, the frequencies of NKT and NK cells are decreased significantly, as shown in this study and in the previously reported literature 37 ; although the exact mechanisms underlying these decreases remain unknown. In addition, the expression of NKG2D is significantly reduced on CD8 + T, NKT and NK cells in SLE, as demonstrated by our and previous studies 37, 38 . Therefore, in the SLE context, the CD8 + T, NKT and NK cells have defects that affect their abilities to kill the target cells in an NKG2D-dependent manner. This detrimental effect has been demonstrated by studies of other AIDs, infectious diseases and tumors 32, [39] [40] [41] . Moreover, we found that the frequency of NKG2D
+ CD4 − cells, including CD8 + T, NK or NKT cell types, did not correlate with that of Treg cells in SLE patients. In contrast, the frequency NKG2D + CD4 + T cells and expression of NKG2D on them were both significantly increased, showing strong cytolytic function towards Treg cells in the in vitro and in vivo assays. Taken together, considering the dysfunction or decreased cell count of NKG2D + CD4 − cells, our results imply that the killing of Tregs is NKG2D
+ CD4 + T cell-specific in the SLE context. It is important to consider that Dai et al. 23 reported that NKG2D + CD4 + T cells in juvenile-onset SLE produced IL-10 and TGF-β, thus having regulatory function. These inconsistencies with our results could be explained by the clinical subject selection; we chose treatment-naive adult patients, while Dai's group chose treatment-experienced (prednisone) juvenile patients, and as such could not exclude the effect of prednisone on NKG2D + CD4 + T cells. In addition, in the present study, we found that NKG2D + CD4 + T cells from SLE * P < 0.05, ** P < 0.01, *** P < 0.001.
Scientific RepoRts | 7: 1288 | DOI:10.1038/s41598-017-01379-y patients could kill monocytes that express MICA/B and ULBP1-3, further indicating the cytolytic capacity of NKG2D + CD4 + T cells towards NKG2DLs-expressing target cells in SLE patients. Spontaneous B6.MRL/lpr and NZBW/F1 mouse models have been used extensively in the studies of immunological mechanisms and therapeutic targets over the years 5, 6 . Each of these models exhibit high levels of serum ANAs and anti-dsDNA antibodies and develop GN. The B6.MRL/lpr mice have a loss-of-function lymphoproliferation mutation (i.e. lpr) within the gene encoding Fas, a cell-surface protein that mediates apoptosis 42 . Defects in Fas signaling allow for increased double-negative CD4 − CD8 − CD3 + B220 + T cell population, thereby leading to lymphadenopathy and splenomegaly 43 . Therefore, the B6.MRL/lpr mice present with dysregulation of T cells and develop AID. The NZBW/F1 lupus mice carry the lupus-susceptibility genes (e.g. Sle1 and Sle3) that are responsible for expansion of autoreactive B cells and autoantibody production [44] [45] [46] . However, in the current study, we observed significantly increased frequency and cell number of NKG2D +
+ T cells in B6.MRL/lpr mice, but not in NZBW/F1 mice. This observation might be due to the completely different genetic backgrounds of the mice or to the different time of lupus development in these two models, both of which could affect NKG2D + cell numbers; however, the exact mechanisms underlying the distinctive increase of NKG2D +
+ T cells in B6.MRL/lpr mice but not in NZBW/F1 mice remain unclear and need to be clarified in future studies.
ULBPs and MICA/B are ligands for NKG2D in humans that are expressed at low levels by many tissues 19 , and expression is upregulated primarily on epithelial cells, mononuclear phagocytes 20 and dendritic cells 22 under stress by infection or malignant transformation 20, 21 . Spada et al. 24 reported increased expression of MICA in kidneys of patients with lupus nephritis and of Rae-1γ and Mult-1 expression in the MRL/lpr lupus mouse model; however, they detected the expression of these NKG2DLs by immunohistochemistry assay and thus could only locate the NKG2DL expression in the glomerular cells in general, but not in any specific cell subset. Dai et al. 23 demonstrated the increased serum level of sMICA in SLE patients but did not determine the source cell of the sMICA. In the present study, we confirmed that there was no detectable expression of NKG2DLs on T cell subsets from SLE patients; however, we did observe that induction by SLE serum or IFN-α could upregulate ULBP1-3 expression, but not MICA/B expression, on Treg cells. Therefore, the increased sMICA level in SLE patients 23 might derive from other immune cells than the Treg cells.
Type I IFN signaling is a key pathogenic pathway in SLE 47 . It has been reported that treatment of the NZB mouse model with IFN-α or the IFN-α inducer polyinosinic:polycytidylic acid (poly I:C) to address AID resulted in significantly decreased Treg cell frequency 48 . Similarly, in our in vitro stimulation assay, we observed induction of Treg cell apoptosis by IFN-α or SLE serum which included high level of IFN-α. However, we were able to exclude effects of apoptosis in the cytotoxicity assay because we performed cell co-culture and adoptive transfer experiments after sorting only viable cells labeled with Annexin V and a vital dye. Therefore, our results clearly demonstrated that the viable Treg cells induced to express ULBP or Mult-1 by IFN-α were lysed by NKG2D + CD4 + T cells rather than by IFN-α-induced apoptosis. Type I IFNs have been implicated as important players in SLE pathogenesis and exposure to anti-IFN-α mAb results in improvement of SLE disease activity 49, 50 . Yet, several studies have reported the reverse function of IFN-α in lupus mouse models 30, 51, 52 , indicating that there are no IFN-α signature profiles for the splenic mononuclear cells of MRL/lpr mice 51 , that IFNAR antibody has no effect 30 and that IFNAR deletion results in even more disease in MRL/lpr mice 52 . It is important to note that all these studies used the MRL/lpr lupus mouse model, which was generated from a series of crosses with strains C57BL/6J (0.3%), C3H/HeDi (12.1%), AKR/J (12.6%) and LG/J (75%) 43 . It should be also be noted that, in our study, we observed substantial protective roles for IFNAR antibody treatment in B6.MRL/lpr mice with C57BL/6 background.
Braun et al. 53 also reported that sustained injection of poly I:C, a potent inducer of IFN-I, into B6.MRL/lpr mice resulted in dramatic aggravation of the renal disease, higher titers of autoantibodies and accumulation of activated lymphocytes. Similarly, Ramani et al. 54 reported that poly I:C could induce IFN-I-dependent crescentic GN in B6.MRL/lpr mice, indicating that IFN-I signaling contributed to the worsened SLE disease of these mice. Moreover, introducing a null mutation for the IFN-I receptor gene into the B6.MRL/lpr background mice resulted in dramatically decreased immune complex deposition in the kidney and in reduced lymphadenopathy 53 . Thus, the difference in potential for IFN-α function in lupus might be dependent upon the different mouse models used in each study, suggesting that explanation of the related results is founded in the genetic background of the involved mice.
Compared with the well-developed IFN-α antibody therapy in SLE 49, 50 , we found that NKG2D antibody treatment has similar effects in B6.MRL/lpr mice, consistent with previous findings in mouse models of non-obese diabetes, collagen-induced arthritis and colitis 31, 55, 56 . A recent report on clinical trials of NKG2D antibody against Crohn's disease revealed a significant reduction of disease activity after several weeks of treatment 57 . The underlying mechanism might involve blockade of the NKG2D-NKG2DL interaction and avoidance of activation of the NKG2D + T, NK or NKT cells 57 . Nevertheless, NKG2D expression on NK, NKT and CD8 + T cells was markedly decreased in SLE patients, while the CD4 + T cells showed increased NKG2D expression. The mechanism underlying the amelioration of SLE disease after NKG2D antibody treatment might involve blockade of the interaction between NKG2D
+ CD4 + T cells and Treg cells, thereby causing restoration of the Treg frequency as observed in treated mice. Given that NKG2DLs are extensively expressed on non-T cells, such as monocytes and glomeruli, in SLE or lupus nephritis 16, 24 , NKG2D antibody therapy would also be expected to block the mutual activation of these cells with NKG2D +
+ T cells. Thus, subsequent studies should investigate the precise mechanism of this significant amelioration in SLE achieved by NKG2D antibody therapy and should identify more specific targets for clinical therapy for SLE.
In conclusion, our findings reveal unique contributions of NKG2D + CD4 + T cells and their killing effect on ULBP + (Mult-1 + ) Treg cells in the pathogenesis of SLE and highlight the NKG2D-NKG2DL interaction in SLE. These results improve our understanding of SLE clinical phenomena and will guide future studies of targeted therapies in SLE patients.
